JP2013512277A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512277A5
JP2013512277A5 JP2012542076A JP2012542076A JP2013512277A5 JP 2013512277 A5 JP2013512277 A5 JP 2013512277A5 JP 2012542076 A JP2012542076 A JP 2012542076A JP 2012542076 A JP2012542076 A JP 2012542076A JP 2013512277 A5 JP2013512277 A5 JP 2013512277A5
Authority
JP
Japan
Prior art keywords
compound
salt
pharmaceutically acceptable
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512277A (ja
JP5709889B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057359 external-priority patent/WO2011066183A1/en
Publication of JP2013512277A publication Critical patent/JP2013512277A/ja
Publication of JP2013512277A5 publication Critical patent/JP2013512277A5/ja
Application granted granted Critical
Publication of JP5709889B2 publication Critical patent/JP5709889B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542076A 2009-11-30 2010-11-19 新規スピロピペリジン化合物 Expired - Fee Related JP5709889B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26518109P 2009-11-30 2009-11-30
US61/265,181 2009-11-30
PCT/US2010/057359 WO2011066183A1 (en) 2009-11-30 2010-11-19 Novel spiropiperidine compounds

Publications (3)

Publication Number Publication Date
JP2013512277A JP2013512277A (ja) 2013-04-11
JP2013512277A5 true JP2013512277A5 (US07714131-20100511-C00001.png) 2013-11-14
JP5709889B2 JP5709889B2 (ja) 2015-04-30

Family

ID=43384775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542076A Expired - Fee Related JP5709889B2 (ja) 2009-11-30 2010-11-19 新規スピロピペリジン化合物

Country Status (25)

Country Link
US (1) US8822486B2 (US07714131-20100511-C00001.png)
EP (1) EP2507228B1 (US07714131-20100511-C00001.png)
JP (1) JP5709889B2 (US07714131-20100511-C00001.png)
KR (1) KR101410103B1 (US07714131-20100511-C00001.png)
CN (1) CN102648195B (US07714131-20100511-C00001.png)
AR (1) AR078948A1 (US07714131-20100511-C00001.png)
AU (1) AU2010324987B2 (US07714131-20100511-C00001.png)
BR (1) BR112012012903A2 (US07714131-20100511-C00001.png)
CA (1) CA2781292C (US07714131-20100511-C00001.png)
CL (1) CL2012001321A1 (US07714131-20100511-C00001.png)
CR (1) CR20120296A (US07714131-20100511-C00001.png)
DO (1) DOP2012000139A (US07714131-20100511-C00001.png)
EA (1) EA020507B1 (US07714131-20100511-C00001.png)
EC (1) ECSP12011930A (US07714131-20100511-C00001.png)
ES (1) ES2526568T3 (US07714131-20100511-C00001.png)
GT (1) GT201200164A (US07714131-20100511-C00001.png)
IL (1) IL219594A0 (US07714131-20100511-C00001.png)
MA (1) MA33840B1 (US07714131-20100511-C00001.png)
MX (1) MX2012006233A (US07714131-20100511-C00001.png)
NZ (1) NZ600203A (US07714131-20100511-C00001.png)
PE (1) PE20121474A1 (US07714131-20100511-C00001.png)
TN (1) TN2012000248A1 (US07714131-20100511-C00001.png)
TW (1) TW201141866A (US07714131-20100511-C00001.png)
WO (1) WO2011066183A1 (US07714131-20100511-C00001.png)
ZA (1) ZA201203055B (US07714131-20100511-C00001.png)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
CA2813639A1 (en) 2010-10-08 2012-04-12 Mochida Pharmaceutical Co. Ltd. Cyclic amide derivative
BR112013027883A2 (pt) 2011-04-27 2017-08-08 Mochida Pharm Co Ltd novo derivado de 1-óxido de 3-hidroxiisotiazol
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
CA2905726C (en) * 2013-03-14 2022-05-31 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
EA201690888A1 (ru) 2013-11-14 2016-10-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
PE20210640A1 (es) 2018-02-13 2021-03-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
ES2962674T3 (es) 2018-07-13 2024-03-20 Gilead Sciences Inc Inhibidores PD-1/PD-L1
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
BRPI0409078A (pt) 2003-04-04 2006-04-18 Merck & Co Inc composto, métodos para o tratamento ou prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, para o tratamento ou prevenção de obesidade, para o tratamento ou prevenção de um distúrbio relacionado com a obesidade, para o tratamento ou prevenção de diabete melito, para o tratamento ou prevenção da disfunção sexual masculina ou feminina e para o tratamento ou prevenção de disfunção erétil, composição farmacêutica, métodos para o tratamento de disfução erétil em um mamìfero, para o tratamento de diabete em um mamìfero e para o tratamento de obesidade em um mamìfero, e, uso de um composto
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
EP1737809B1 (en) * 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
EP1795527B1 (en) * 2004-09-07 2009-04-22 Banyu Pharmaceutical Co., Ltd. Carbamoyl-substituted spiro derivative
AU2007275931B2 (en) * 2006-07-19 2011-06-16 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
JPWO2008038692A1 (ja) * 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
PL2125827T3 (pl) * 2006-12-29 2011-04-29 Hoffmann La Roche Pochodne azaspiro
JP2010524932A (ja) * 2007-04-16 2010-07-22 アムジエン・インコーポレーテツド 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質
WO2009054479A1 (ja) 2007-10-26 2009-04-30 Japan Tobacco Inc. スピロ環化合物及びその医薬用途
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Similar Documents

Publication Publication Date Title
JP2013512277A5 (US07714131-20100511-C00001.png)
JP2013508279A5 (US07714131-20100511-C00001.png)
JP2012526728A5 (US07714131-20100511-C00001.png)
JP2013507423A5 (US07714131-20100511-C00001.png)
JP2014500861A5 (US07714131-20100511-C00001.png)
JP2013537203A5 (US07714131-20100511-C00001.png)
JP2016006118A5 (US07714131-20100511-C00001.png)
JP2007302689A5 (US07714131-20100511-C00001.png)
JP2015500843A5 (US07714131-20100511-C00001.png)
JP2013518107A5 (US07714131-20100511-C00001.png)
JP2013032389A5 (US07714131-20100511-C00001.png)
JP2009523760A5 (US07714131-20100511-C00001.png)
JP2013503846A5 (US07714131-20100511-C00001.png)
JP2014530900A5 (US07714131-20100511-C00001.png)
JP2010077141A5 (US07714131-20100511-C00001.png)
JP2013510123A5 (US07714131-20100511-C00001.png)
JP2012512863A5 (US07714131-20100511-C00001.png)
JP2006524660A5 (US07714131-20100511-C00001.png)
JP2011504903A5 (US07714131-20100511-C00001.png)
JP2011518833A5 (US07714131-20100511-C00001.png)
JP2014516033A5 (US07714131-20100511-C00001.png)
JP2013542261A5 (US07714131-20100511-C00001.png)
JP2015508092A5 (US07714131-20100511-C00001.png)
JP2013513607A5 (US07714131-20100511-C00001.png)
JP2015516419A5 (US07714131-20100511-C00001.png)